- Biosante presented 9/12/11 at Rodman and Renshaw conference, along with most of the stocks I cover - click here for full schedule of biotech webcasts and links to my notes.
- Find more detailed info on Libigel on the BPAX research page.
- Keep reading for my complete webcast notes - new info is bolded:
--SYNERGY is primary registrational trial for cusirsen OGX-011, enrollment is moving along very nicely
--survival correlation w/ clusterin levels- what creates resistance to clusterin? what happens in nonresponsive tumors? Think about herceptin and HER2 expression. It doesn't matter so much where patients started. Clusterin is upregulated in repsonse to stress of treatment - we are trying to prevent the upregulation
--We are not exploring a diagnostic yet, data on clusterin levels is more to supplement the regulatory package
2) Conjugate - very excited about translating conjugate technology into pipleine as part of 5x15 as well [but first 4 of 5 programs announced use LNP...]
Question and Answer session-